Literature DB >> 12692477

Different chromogranin immunoreactivity between prion and a-beta amyloid plaque.

Claire-Marie Rangon1, Stéphane Haïk, Baptiste A Faucheux, Marie-Helène Metz-Boutigue, Françoise Fierville, Jean-Paul Fuchs, Jean-Jacques Hauw, Dominique Aunis.   

Abstract

Brain lesions in Creutzfeldt-Jakob disease (CJD) include spongiform change, neuronal loss, amyloid plaques, astrogliosis and microglial activation. Microglia are thought to play a key role in prion-induced neurodegeneration. However, the intermediate molecules supporting relationships between neurons and microglia are still unknown. Chromogranins (Cg) are soluble glycophosphoproteins that can activate microglial cells leading to a neurotoxic phenotype. The immunoreactive patterns of CgA and CgB were investigated in CJD and compared to those observed in Alzheimer's disease. We found that CgB, but not CgA, immunoreactivity was selectively associated with prion protein deposits, whereas CgA was only seen in Abeta plaques. This suggests a specific influence of the constitutive amyloid protein on chromogranin secretion and a role of CgB in the CJD neurodegenerative process.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12692477     DOI: 10.1097/00001756-200304150-00019

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  12 in total

Review 1.  Catestatin: a multifunctional peptide from chromogranin A.

Authors:  Sushil K Mahata; Manjula Mahata; Maple M Fung; Daniel T O'Connor
Journal:  Regul Pept       Date:  2010-01-28

2.  The normal cellular prion protein (PrPc) is strongly expressed in bovine endocrine pancreas.

Authors:  W M Amselgruber; M Büttner; T Schlegel; M Schweiger; E Pfaff
Journal:  Histochem Cell Biol       Date:  2005-10-06       Impact factor: 4.304

3.  Comparative profiling of highly enriched 22L and Chandler mouse scrapie prion protein preparations.

Authors:  Roger A Moore; Andrew Timmes; Phillip A Wilmarth; Suzette A Priola
Journal:  Proteomics       Date:  2010-08       Impact factor: 3.984

Review 4.  Neuroinflammatory processes in Alzheimer's disease.

Authors:  Michael T Heneka; M Kerry O'Banion; Dick Terwel; Markus Peter Kummer
Journal:  J Neural Transm (Vienna)       Date:  2010-07-15       Impact factor: 3.575

5.  Monitoring CSF proteome alterations in amyotrophic lateral sclerosis: obstacles and perspectives in translating a novel marker panel to the clinic.

Authors:  Nils von Neuhoff; Tonio Oumeraci; Thomas Wolf; Katja Kollewe; Peter Bewerunge; Boris Neumann; Benedikt Brors; Johannes Bufler; Ulrich Wurster; Brigitte Schlegelberger; Reinhard Dengler; Marc Zapatka; Susanne Petri
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

6.  Prion disease induced alterations in gene expression in spleen and brain prior to clinical symptoms.

Authors:  Hyeon O Kim; Greg P Snyder; Tyler M Blazey; Richard E Race; Bruce Chesebro; Pamela J Skinner
Journal:  Adv Appl Bioinform Chem       Date:  2008-09-07

7.  Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers.

Authors:  Holger Jahn; Stefan Wittke; Petra Zürbig; Thomas J Raedler; Sönke Arlt; Markus Kellmann; William Mullen; Martin Eichenlaub; Harald Mischak; Klaus Wiedemann
Journal:  PLoS One       Date:  2011-10-26       Impact factor: 3.240

8.  A Chronic Fatigue Syndrome - related proteome in human cerebrospinal fluid.

Authors:  James N Baraniuk; Begona Casado; Hilda Maibach; Daniel J Clauw; Lewis K Pannell; Sonja Hess S
Journal:  BMC Neurol       Date:  2005-12-01       Impact factor: 2.474

9.  Catestatin and vasostatin concentrations in healthy dogs.

Authors:  Thanikul Srithunyarat; Ragnvi Hagman; Odd V Höglund; Ulf Olsson; Mats Stridsberg; Supranee Jitpean; Anne-Sofie Lagerstedt; Ann Pettersson
Journal:  Acta Vet Scand       Date:  2017-01-03       Impact factor: 1.695

10.  Biological function and clinical relevance of chromogranin A and derived peptides.

Authors:  Maria Angela D'amico; Barbara Ghinassi; Pascal Izzicupo; Lamberto Manzoli; A Di Baldassarre
Journal:  Endocr Connect       Date:  2014-04-29       Impact factor: 3.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.